Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von NightTrain 

Illumina Inc. diskutieren

Illumina Inc.

WKN: 927079 / Symbol: ILMN / Name: Illumina / Aktie / Ausrüstung & Versorgung / Large Cap /

125,52 €
-0,22 %

Einschätzung Buy
Rendite (%) 5,48 %
Kursziel 140,03
Veränderung
Endet am 16.08.25

Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Daiwa Capital Markets from a "neutral" rating to a "buy" rating. They now have a $154.00 price target on the stock, up previously from $120.00.
Ratings data for ILMN provided by MarketBeat

Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Daiwa America to a "strong-buy" rating.
Ratings data for ILMN provided by MarketBeat

Illumina, Inc. (NASDAQ: ILMN) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Ratings data for ILMN provided by MarketBeat

Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating.
Ratings data for ILMN provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,09 %
Kursziel 150,00
Veränderung
Endet am 14.09.25

Hey there, fellow investors! I've been diving into Illumina lately, and I've got to say, I'm pretty excited about what I'm seeing. Sure, they've had a rough couple of years, but it looks like they might be turning the corner. First off, that EU court ruling is a big win for Illumina. Not only does it save them a hefty €432 million fine, but it also shows they're not afraid to stand up for themselves. That's the kind of grit I like to see in a company! Now, let's talk about their tech. Illumina's not just riding the AI wave - they're making waves of their own. Their PrimateAI-3D tool is like a crystal ball for genetic diseases. It's the kind of innovation that could revolutionize healthcare. And speaking of revolutions, have you seen their earnings forecast? It's like watching a rocket take off. Their EPS estimates have more than doubled in just two months! That's the kind of momentum that gets my investor senses tingling. Sure, their P/E ratio is a bit high at 34.3x, but in the world of biotech, that's not too shabby. Plus, with their earnings expected to grow by 24% next year, they might just grow into that valuation. Now, I'm not saying Illumina is a guaranteed moonshot. They've still got challenges ahead, and the market can be as unpredictable as a cat in a room full of laser pointers. But with their innovative tech, improving financials, and recent legal victories, I think Illumina might just have what it takes to light up your portfolio. What do you think? Ready to illuminate your investment strategy with ILMN?